CareRx (CRRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $92.0 million, down year-over-year but up from Q1 2024, mainly due to changes in average beds serviced.

• Adjusted EBITDA grew to $7.5 million, with margin improvement to 8.2%, driven by cost savings and improved supply terms.

• Net loss of $1.4 million, compared to net income of $1.9 million in Q2 2023, mainly due to non-cash adjustments and a one-time intangible asset impairment from the sale of a non-core pharmacy.

• Leadership changes included a new board chair, interim CFO, and executive team strengthening.

• Ongoing operational optimization and cost-saving initiatives are driving margin and productivity gains.

Financial highlights

• Revenue declined from $94.5 million in Q2 2023 to $92.0 million in Q2 2024, but increased from $89.7 million in Q1 2024, partly due to two additional revenue-generating days.

• Adjusted EBITDA increased to $7.5 million from $7.0 million year-over-year and was up 1% sequentially.

• Adjusted EBITDA margin rose 70 basis points year-over-year to 8.2%.

• Net loss of $1.4 million, compared to net income of $1.9 million in Q2 2023 and a loss of $0.5 million in Q1 2024.

• Cash provided by operations in Q2 2024 was $8.1 million, up from $5.3 million in Q2 2023.

Outlook and guidance

• Management expects continued margin and adjusted EBITDA growth, with a robust pipeline and more than half of targeted bed growth for the second half already secured.

• Margins expected to remain relatively stable, with some seasonal labor cost variability.

• Full benefit of the amended pharmaceutical supply agreement expected in Q3 2024.

• Focus remains on productivity, efficiency, and cost management to position for future growth opportunities in the seniors living sector.

• Growth strategy includes organic bed wins, expansion into new care settings, and continued M&A in a fragmented market.